Brief: Elicio Therapeutics - Presents Updated Preclinical Data On Eli-005
29/03/2022 19:41
March 29 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS - PRESENTS UPDATED PRECLINICAL DATA ON ELI-005,
DEMONSTRATING IT INDUCES POTENT CROSS-REACTIVE CELLULAR, HUMORAL IMMUNITY TO
SARS-COV-2
* ELICIO THERAPEUTICS - ADMINISTRATION OF ELI-005 PRODUCED RAPID
SEROCONVERSION,
BOOSTING OF SERUM IGG WITH SPECIFICITY AGAINST NUMEROUS RBD VARIANTS
Source text for Eikon: ID:nGNXb08lhz
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)